Vincerx Pharma (NASDAQ:VINC) PT Lowered to $2.00 at Leerink Partners

Vincerx Pharma (NASDAQ:VINC) had its price target reduced by Leerink Partners from $4.00 to $2.00 in a research report report published on Tuesday, Benzinga reports. They currently have an outperform rating on the stock.

Vincerx Pharma Price Performance

VINC stock opened at $0.39 on Tuesday. The business has a fifty day moving average price of $0.67 and a 200 day moving average price of $1.06. Vincerx Pharma has a fifty-two week low of $0.38 and a fifty-two week high of $9.37. The stock has a market capitalization of $11.63 million, a price-to-earnings ratio of -0.30 and a beta of 1.49.

Vincerx Pharma (NASDAQ:VINC) last announced its earnings results on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.12. On average, equities analysts expect that Vincerx Pharma will post -0.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vincerx Pharma

A number of institutional investors have recently modified their holdings of VINC. Vanguard Group Inc. boosted its position in Vincerx Pharma by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after buying an additional 153,575 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Vincerx Pharma by 359.1% during the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after acquiring an additional 256,967 shares during the period. Finally, Armistice Capital LLC acquired a new position in shares of Vincerx Pharma during the second quarter valued at $1,610,000. 44.02% of the stock is owned by institutional investors.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.